Loading..

Deciphera Pharmaceuticals, Inc. (DCPH) Report Analysis

Corporate Events

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Value Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Value Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Growth Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Growth Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) ...

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Index

Negative

Deciphera Pharmaceuticals, Inc. Appoints Kelley...

2022-06-16 11:00:00

Deciphera Pharmaceuticals, Inc. announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy b...

Neutral

Deciphera Pharmaceuticals, Inc. Presents at 202...

2022-06-02 11:00:00

Deciphera Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New Yo...

Neutral

Deciphera Pharmaceuticals, Inc. Presents at The...

2022-05-09 14:47:00

Deciphera Pharmaceuticals, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 10:00 AM. Venue: Lotte New York Pala...

Neutral

Deciphera Pharmaceuticals, Inc., Q1 2022 Earnin...

2022-05-02 12:00:00

Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q1, 2...

2022-05-02 12:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Deciphera Pharmaceuticals, Inc. - Shareholder/A...

2022-04-26 11:36:00

Annual Meeting of Stockholders

Neutral

Deciphera Pharmaceuticals, Inc., Annual General...

2022-04-26 11:36:00

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022, at 08:30 US Eastern Standard Time. Agenda: To consider electing three d...

Negative

Deciphera Pharmaceuticals, Inc. has filed a Fol...

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security...

Negative

Deciphera Pharmaceuticals, Inc. has completed a...

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $149.902512 million. Security Name: Common Stock...

Negative

Deciphera Pharmaceuticals, Inc. has completed a...

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million. Security Name: Common Stock Secu...

Positive

Deciphera Pharmaceuticals, Inc Presents Preclin...

2022-04-12 19:50:00

Deciphera Pharmaceuticals, Inc. announced the presentation of preclinical data for DCC-3116, the Company’s first-in-class ULK kinase inhibitor...

Neutral

JMP Securities LLC, the JMP Securities Life Sci...

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Mad...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Clinigen Group plc Signs Distribution Agreement...

2022-02-09 07:00:00

Clinigen Group plc announced it has signed a distribution agreement, with Deciphera Pharmaceuticals for the supply and distribution of QINLOCK...

Neutral

Deciphera Pharmaceuticals, Inc. has filed a She...

2022-02-08 00:00:00

Deciphera Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $29.079697 million. Security Name: Common Stock Securities...

Neutral

Deciphera Pharmaceuticals, Inc. Presents at SCO...

2022-02-03 10:27:00

Deciphera Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-08-2022 03:35 PM. Venue: Orlanda, Florida, United States. Speakers: Jennife...

Neutral

Deciphera Pharmaceuticals, Inc. Presents at 4th...

2022-02-02 12:00:00

Deciphera Pharmaceuticals, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 08:30 AM. Speakers: Steven L. Hoerter, President, ...

Neutral

Deciphera Pharmaceuticals, Inc., Q4 2021 Earnin...

2022-02-01 12:15:00

Deciphera Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 08, 2022

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q4, 2...

2022-02-01 12:15:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q4, 2021 results on Feb 08, 2022

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Positive

Deciphera Announces Approval of QINLOCK® in the...

2021-12-21 13:44:00

Deciphera Pharmaceuticals, Inc. announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...

Negative

Deciphera Pharmaceuticals, Inc. Announces Restr...

2021-11-30 13:42:00

Deciphera Pharmaceuticals, Inc. announced a corporate restructuring intended to prioritize clinical development of select programs, streamline...

Positive

Deciphera Pharmaceuticals, Inc. Receives Europe...

2021-11-22 12:00:00

Deciphera Pharmaceuticals, Inc. announced that the European Commission (EC) has approved QINLOCK® (ripretinib) in the European Union (EU) for ...

Positive

Deciphera Pharmaceuticals, Inc. Announcing Top-...

2021-11-05 20:15:00

On November 5, 2021, Deciphera Pharmaceuticals, Inc., Zai Lab Limited’s partner, announced top-line results from the INTRIGUE Phase 3 clinical...

Positive

Deciphera Pharmaceuticals, Inc. Announces Top-L...

2021-11-05 11:00:00

Deciphera Pharmaceuticals, Inc. announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestin...

Neutral

Deciphera Pharmaceuticals, Inc. - Special Call

2021-11-05 11:00:00

To discuss Top-Line Results from the INTRIGUE Phase 3 Clinical Study

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Deciphera Pharmaceuticals, Inc., Q3 2021 Earnin...

2021-10-26 11:00:00

Deciphera Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q3, 2...

2021-10-26 11:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Nov 02, 2021

Positive

Deciphera Pharmaceuticals, Inc. Announces Appro...

2021-10-12 11:00:00

Deciphera Pharmaceuticals, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for QINLOCK (ripret...

Positive

Deciphera Pharmaceuticals, Inc. Presents Precli...

2021-10-07 13:00:00

Deciphera Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company’s first-in-class selective ULK kinase inhibito...

Positive

Deciphera Pharmaceuticals, Inc. Announces Posit...

2021-09-17 20:02:00

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...

Positive

Deciphera Pharmaceuticals Presents New Clinical...

2021-09-17 11:00:00

Deciphera Pharmaceuticals, Inc. announced four e-poster presentations at the ESMO Congress 2021. The presentations include updated preliminary...

Neutral

Deciphera Pharmaceuticals, Inc. - Special Call

2021-09-10 11:00:00

To review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summ...

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at Mor...

2021-09-02 11:00:00

Deciphera Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 02:45 PM. Venue: New Windsor,...

Neutral

Deciphera Pharmaceuticals, Inc. Presents at Eur...

2021-08-23 12:06:00

Deciphera Pharmaceuticals, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte...

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q2, 2...

2021-07-27 11:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Aug 03, 2021

Neutral

Deciphera Pharmaceuticals, Inc., Q2 2021 Earnin...

2021-07-27 11:00:00

Deciphera Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Positive

Deciphera Announces First Patient Treated in Ph...

2021-06-30 20:01:00

Deciphera Pharmaceuticals, Inc. announced dose administration for the first patient in the Phase 1, multicenter, open-label, first-in-human st...

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Value Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Value Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Value Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Value Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Growth Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell 3000E Growth Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Growth Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Growth Index

Positive

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Index

2022-06-24 00:00:00

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) added to Russell Microcap Index

Negative

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

2022-06-16 11:00:00

Deciphera Pharmaceuticals, Inc. announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company’s business development efforts as well as supporting corporate strategy initiatives. Ms. Dealhoy brings over 20 years of experience in the life science sector with a focus on driving innovation through strategic partnerships. She joins Deciphera from Novartis, where she most recently served as the Vice President of Business Development for the Oncology Division. Ms. Dealhoy had a cumulative 10 years of experience at Novartis in a variety of roles including as Vice President of U.S. Business Development for the Pharmaceutical Division and Global Head of Business Development and M&A for the Consumer Division. Prior to Novartis, Ms. Dealhoy was a Life Science Leader in Deloitte’s Financial Advisory practice where she worked with biotechnology and pharmaceutical companies to develop and implement strategies to drive growth and unlock value. She has also held leadership roles in business development and R&D at Merck and Eli Lilly. She received her Bachelor of Science in Biochemistry from Queen’s University in Canada.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM

2022-06-02 11:00:00

Deciphera Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 10:00 AM

2022-05-09 14:47:00

Deciphera Pharmaceuticals, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 10:00 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

2022-05-02 12:00:00

Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

2022-05-02 12:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Deciphera Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-26 11:36:00

Annual Meeting of Stockholders

Neutral

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

2022-04-26 11:36:00

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022, at 08:30 US Eastern Standard Time. Agenda: To consider electing three directors, Steven L. Hoerter, Susan L. Kelley, M.D., and John R. Martin, to serve as Class II directors, as nominated by the board of directors of Deciphera Pharmaceuticals, Inc., to hold office until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation, or removal; to approve, on a non-binding, advisory basis, the compensation of named executive officers, as disclosed in this proxy statement; to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as the company’s independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting and at any adjournments or postponements thereof.

Negative

Deciphera Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Security Name: Pre Funded Warrants Security Type: Equity Warrant

Negative

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $149.902512 million.

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $149.902512 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,251,239 Price\Range: $10 Discount Per Security: $0.5 Security Name: Pre Funded Warrants Security Type: Equity Warrant Securities Offered: 9,748,761 Price\Range: $9.99 Discount Per Security: $0.5

Negative

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

2022-04-26 00:00:00

Deciphera Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million. Security Name: Common Stock Security Type: Common Stock Security Name: Common Stock Security Type: Common Stock Securities Offered: 294,275 Security Name: Common Stock Security Type: Common Stock Securities Offered: 172,094 Transaction Features: At the Market Offering

Positive

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

2022-04-12 19:50:00

Deciphera Pharmaceuticals, Inc. announced the presentation of preclinical data for DCC-3116, the Company’s first-in-class ULK kinase inhibitor, in combination with KRASG12C inhibitors in non-small cell lung cancer (NSCLC) models at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana. Results from the preclinical studies showed that KRASG12C inhibitors, sotorasib and adagrasib, activate ULK-mediated autophagy as an adaptive treatment resistance mechanism. DCC-3116 in combination with sotorasib and with adagrasib inhibited ULK kinase activation and the resulting autophagic flux in a KRASG12C mutated NSCLC cell line. Results demonstrated that DCC-3116 in combination with sotorasib and with adagrasib translated to deeper and longer tumor regressions in vivo. The study also demonstrated that DCC-3116 in combination with sotorasib outperformed both single agent sotorasib and the combination of sotorasib and chloroquine, a nonspecific lysosomal inhibitor of autophagy. Results of the preclinical studies were as follows: Treatment of mutant KRASG12C NSCLC cell lines with KRASG12C inhibitors, sotorasib and adagrasib, induced autophagy via activation of ULK1/2 kinases as measured by an increase in ULK-mediated phosphorylation of the key ULK autophagy substrate ATG13 and resulting increase in autophagic flux. In mutant KRASG12C NSCLC cell lines, DCC-3116 inhibited ULK kinase activation by both sotorasib and adagrasib, as measured by a decrease in phosphorylated ATG13 and resulting autophagic flux. In the H358 KRASG12C NSCLC xenograft model, the combination of DCC-3116 and sotorasib resulted in deeper and longer tumor regressions compared to all single agent sotorasib cohorts. In the Calu-1 KRASG12C NSCLC xenograft model, the combination of DCC-3116 and sotorasib resulted in tumor regressions and outperformed both single agent sotorasib and the combination of sotorasib and chloroquine. In the LU11554 KRASG12C NSCLC patient derived xenograft model, the efficacy for the combination of DCC-3116 with sotorasib or with adagrasib increased tumor growth inhibition compared to sotorasib or adagrasib alone. DCC-3116 is currently being investigated in a Phase 1, multicenter, open-label, first-in-human study designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of DCC-3116 as a single agent and in combination with trametinib, an FDA approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. Initial data from the single agent dose escalation portion of the Phase 1 study is expected in the second half of 2022. The Company expects to initiate Phase 1 study dose escalation cohorts in the second half of 2022 in combination with trametinib in patients with selected mutations in advanced or metastatic pancreatic ductal adenocarcinoma, NSCLC, colorectal cancer, and melanoma. Planning is underway to add a combination with a KRASG12C inhibitor in NSCLC to the ongoing Phase 1 study, subject to feedback from regulatory authorities.

Neutral

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Clinigen Group plc Signs Distribution Agreement with Deciphera Pharmaceuticals

2022-02-09 07:00:00

Clinigen Group plc announced it has signed a distribution agreement, with Deciphera Pharmaceuticals for the supply and distribution of QINLOCK® into multiple countries across the globe. QINLOCK® was approved by the European Medicines Agency in November 2021 for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. Under the agreement, Clinigen will supply QINLOCK® into multiple countries where it is not yet commercially available. Clinigen will act as the main point of contact for healthcare professionals wanting to access QINLOCK®, managing all elements of the process including order and enquiry management, regulatory compliance, and logistics.

Neutral

Deciphera Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $29.079697 million.

2022-02-08 00:00:00

Deciphera Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $29.079697 million. Security Name: Common Stock Securities Offered: 3,541,985 Transaction Features: ESOP Related Offering

Neutral

Deciphera Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-08-2022 03:35 PM

2022-02-03 10:27:00

Deciphera Pharmaceuticals, Inc. Presents at SCOPE Summit 2022, Feb-08-2022 03:35 PM. Venue: Orlanda, Florida, United States. Speakers: Jennifer Sydney Goldman, Director, Clinical Business Operations.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 08:30 AM

2022-02-02 12:00:00

Deciphera Pharmaceuticals, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 08:30 AM. Speakers: Steven L. Hoerter, President, CEO & Director.

Neutral

Deciphera Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 08, 2022

2022-02-01 12:15:00

Deciphera Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 08, 2022

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

2022-02-01 12:15:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q4, 2021 results on Feb 08, 2022

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Positive

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

2021-12-21 13:44:00

Deciphera Pharmaceuticals, Inc. announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for QINLOCK® (ripretinib) in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. In INVICTUS, QINLOCK demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001)2. Secondary endpoints include Objective Response Rate (ORR) as determined by independent radiologic review using modified RECIST and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504)2 In addition, QINLOCK demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36).

Negative

Deciphera Pharmaceuticals, Inc. Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations

2021-11-30 13:42:00

Deciphera Pharmaceuticals, Inc. announced a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company’s cash runway. Following a detailed review of its portfolio and growth opportunities, Deciphera will focus its resources on the continued advancement of vimseltinib and DCC-3116, while discontinuing the rebastinib program. The Company will streamline commercial operations for QINLOCK® in the U.S. and focus commercialization efforts on a select number of key European markets. These changes are expected to result in a significant reduction in operating expenses and extend the Company’s cash runway into 2024. The Company intends to reduce expenses and extend its existing cash runway through the following restructuring initiatives and prioritization of its pipeline: The Company will implement an organizational restructuring that will result in a workforce reduction of approximately 35%, or approximately 140 positions. The restructuring is expected to affect U.S. employees across all areas of the organization including the QINLOCK commercial team, research and development, and general and administrative support functions. Deciphera will remain focused on the commercialization of QINLOCK for the treatment of fourth-line GIST in the U.S. with a reduced commercial team. In Europe, Deciphera will maintain a limited direct commercial presence that will support the launch of QINLOCK in two key markets, Germany and France, and work to provide access to QINLOCK in additional European countries through other channels. Further clinical development of QINLOCK will be discontinued, including the Phase 1b/2 MEK combination study, which had been planned to start in the fourth quarter of 2021. Deciphera is prioritizing the clinical development of its vimseltinib and DCC-3116 programs, discontinuing the development of the rebastinib program, and continuing with a focused investment in its next generation of research programs, designed to provide first-in-class or best-in-class treatments for patients. Vimseltinib: The Company expects to initiate the Phase 3 MOTION study for vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of CSF1R, for the treatment of tenosynovial giant cell tumor (TGCT) before the end of the year. DCC-3116: Deciphera will continue to advance the clinical development of DCC-3116, a first-in-class ULK kinase inhibitor designed to inhibit autophagy for the treatment of patients with advanced or metastatic tumors with a mutant RAS or RAF gene. DCC-3116 is currently being investigated as a single agent and in combination with trametinib in an ongoing Phase 1 study. Deciphera expects to present initial data from the dose escalation phase of the Phase 1 study in 2022. In addition to the ongoing Phase 1 study, the Company is actively exploring preclinical combinations of DCC-3116 with multiple additional targeted oncology agents with diverse mechanisms of action. Rebastinib: Deciphera will discontinue development of rebastinib, which was expected to enter a Phase 3 study in patients with platinum-resistant ovarian cancer in 2022. Research: The Company intends to continue to invest in the development of new product candidates using its novel switch-control inhibitor approach. Deciphera had cash, cash equivalents, and marketable securities of $392 million as of September 30, 2021. Collectively, these changes are expected to extend the Company’s cash runway into 2024 through significant reductions in the Company’s operating expenses including personnel-related costs and external expenses. Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.

Positive

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

2021-11-22 12:00:00

Deciphera Pharmaceuticals, Inc. announced that the European Commission (EC) has approved QINLOCK® (ripretinib) in the European Union (EU) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The EC decision is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. In September 2021, QINLOCK was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST. The QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. In INVICTUS, QINLOCK demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints include Objective Response Rate (ORR) as determined by independent radiologic review using modified RECIST and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504). In addition, QINLOCK demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36). The most frequently observed adverse drug reactions (=25%) in a pooled safety population (n=392) treated with QINLOCK were fatigue, alopecia, nausea, myalgia, constipation, diarrhea, palmar-plantar erythrodysesthesia syndrome (PPES), weight decreased, and vomiting. In the INVICTUS study, adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received QINLOCK.

Positive

Deciphera Pharmaceuticals, Inc. Announcing Top-Line Results from the Intrigue Phase 3 Clinical Study of Qinlock in Patients with Gastrointestinal Stromal Tumor

2021-11-05 20:15:00

On November 5, 2021, Deciphera Pharmaceuticals, Inc., Zai Lab Limited’s partner, announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK compared to sunitinib in patients with GIST previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib.

Positive

Deciphera Pharmaceuticals, Inc. Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

2021-11-05 11:00:00

Deciphera Pharmaceuticals, Inc. announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib. The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK compared to sunitinib in patients with GIST previously treated with imatinib. In the study, 453 patients were randomized 1:1 to either QINLOCK 150 mg once daily or sunitinib 50 mg once daily for four weeks followed by two weeks without sunitinib. The study did not achieve the primary efficacy endpoint of progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST). The statistical analysis plan included a hierarchical testing sequence that included testing patients with a KIT exon 11 primary mutation and then in the all patient intent-to-treat (AP) population. In patients with a KIT exon 11 primary mutation, (n=327), QINLOCK demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm (Hazard Ratio [HR] 0.88, p=0.360). Although not formally tested due to the rules of the hierarchical testing sequence, in the AP population QINLOCK demonstrated a mPFS of 8.0 months compared to 8.3 months for the sunitinib arm (HR 1.05, nominal p=0.715). The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK compared to sunitinib in patients with GIST previously treated with imatinib. In the study, 453 patients were randomized 1:1 to either QINLOCK 150 mg once daily or sunitinib 50 mg once daily for four weeks followed by two weeks without sunitinib. The primary endpoint is progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST) in the pre-specified subgroup of patients with a KIT exon 11 mutation (exon 11) and then in the all patient intent-to-treat (AP) population. Secondary endpoints include Objective Response Rate (ORR) as determined by independent radiologic review using modified RECIST and Overall Survival (OS) in both the exon 11 and AP groups. The study is being conducted at 122 investigational sites in 22 countries. Cardiac Dysfunction: In INVICTUS, cardiac failure occurred in 1.2% of the 85 patients who received QINLOCK. In the pooled safety population, cardiac dysfunction (including cardiac failure, acute left ventricular failure, diastolic dysfunction, and ventricular hypertrophy) occurred in 1.7% of 351 patients, including Grade 3 adverse reactions in 1.1% of patients. In INVICTUS, Grade 3 decreased ejection fraction occurred in 2.6% of the 77 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram. Grade 3 decreased ejection fraction occurred in 3.4% of the 263 patients in the pooled safety population who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram. In INVICTUS, cardiac dysfunction led to dose discontinuation in 1.2% of the 85 patients who received QINLOCK. The safety of QINLOCK has not been assessed in patients with a baseline ejection fraction below 50%. Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction.

Neutral

Deciphera Pharmaceuticals, Inc. - Special Call

2021-11-05 11:00:00

To discuss Top-Line Results from the INTRIGUE Phase 3 Clinical Study

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Deciphera Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

2021-10-26 11:00:00

Deciphera Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 02, 2021

2021-10-26 11:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Nov 02, 2021

Positive

Deciphera Pharmaceuticals, Inc. Announces Approval of QINLOCK in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

2021-10-12 11:00:00

Deciphera Pharmaceuticals, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The application for QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study of QINLOCK in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. In INVICTUS, QINLOCK demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate (ORR) and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504). In addition, QINLOCK demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36). The most frequently observed adverse drug reactions (=20%) in patients treated with QINLOCK were fatigue, alopecia, nausea, myalgia, constipation, diarrhea, palmar-plantar erythrodysesthesia syndrome (PPES), weight decreased, vomiting, lipase increased, muscle spasms, arthralgia, headache and dyspnoea. In the INVICTUS study, adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received QINLOCK .

Positive

Deciphera Pharmaceuticals, Inc. Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2021-10-07 13:00:00

Deciphera Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company’s first-in-class selective ULK kinase inhibitor, DCC-3116, in combination with EGFR inhibitors in non-small cell lung cancer (NSCLC) models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Results from the study, presented in a poster titled “DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models” are summarized below. In Vitro Data Show Ability of DCC-3116 to Reduce Autophagy that Develops as a Resistance Mechanism after Treatment with EGFR Inhibitors in NSCLC Cell Lines: EGFR inhibitors gefitinib, erlotinib and osimertinib, and the ErbB-family inhibitor, afatinib, activated autophagy three to four-fold over basal levels as measured by pATG13, a cellular substrate of autophagy-initiating kinases ULK1/2, in the EGFR exon 19-deleted HCC827 NSCLC cell line. DCC-3116, a potent inhibitor of ULK1 and ULK2, was shown to inhibit both basal and EGFR-induced phosphorylation of pATG13. Treatment of the EGFR T790M-mutated NSCLC cell line H1975 with osimertinib or afatinib, which inhibit the T790M mutation, induced autophagy three-fold over basal levels while treatment with gefitinib or erlotinib, which are not able to inhibit the T790M mutation, did not induce ULK-mediated ATG13 phosphorylation. DCC-3116 potently inhibited osimertinib and afatinib-induced phosphorylation of ATG13 and inhibited the increase in autophagosomes induced by these agents. In Vivo Data Show that Combination of DCC-3116 with EGFR Inhibitors Resulted in Significantly Greater Tumor Responses in NSCLC Xenograft Model: The combination of DCC-3116 with osimertinib or afatinib resulted in significantly greater tumor responses than single agent treatments in the H1975 EGFR-mutant xenograft model. The clinical development plan for DCC-3116 will initially focus on documented RAS and RAF cancer mutations, which utilize autophagy for tumor growth and survival. DCC-3116 is currently being investigated in a Phase 1, multicenter, open-label, first-in-human study designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of DCC-3116 as a single agent and in combination with trametinib, a commercially available MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. Following the dose escalation phase, combination expansion cohorts are currently planned in patients with advanced or metastatic pancreatic ductal adenocarcinoma with KRAS or BRAF mutations, non-small cell lung cancer (NSCLC) with KRAS, NRAS, or BRAF mutations, colorectal cancer with KRAS, NRAS, or BRAF mutations, and melanoma with NRAS or BRAF mutations. Combination expansion cohorts are planned to evaluate DCC-3116 in combination with trametinib. Initial data from the Phase 1 dose escalation cohorts is expected in 2022.

Positive

Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

2021-09-17 20:02:00

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission (EC), which has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera’s marketing authorization application (MAA) for ripretinib. The MAA is supported by efficacy results from the pivotal Phase 3 INVICTUS study of QINLOCK in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. In INVICTUS, ripretinib demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate (ORR) and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504). In addition, ripretinib demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36).

Positive

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline At the European Society for Medical Oncology Congress 2021

2021-09-17 11:00:00

Deciphera Pharmaceuticals, Inc. announced four e-poster presentations at the ESMO Congress 2021. The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib in combination with paclitaxel in patients with PROC and updated preliminary results from the ongoing Phase 1/2 study of vimseltinib in patients with TGCT. A long-term update on the Phase 3 INVICTUS study of QINLOCK in patients with advanced gastrointestinal stromal tumors, and results from the expansion phase of the Phase 1 study of ripretinib in patients with KIT-altered metastatic melanoma will also be presented. All e-poster presentations are now available on-demand via the ESMO. Deciphera will also host an investor event featuring key opinion leaders to discuss the rebastinib and vimseltinib data September 17, 2021, at 10 AM ET. A live webcast of the event may be accessed through the “Investors” section of Deciphera’s website. A replay of the webcast will be available following the event. The Phase 1b/2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor activity, and pharmacokinetics of rebastinib in patients with advanced or metastatic solid tumors. The data presented is from the second stage of Part 2 of the Simon two-stage design in PROC. As of the June 22, 2021 cutoff date, 38 patients with PROC initiated treatment with rebastinib and paclitaxel and are included in the safety population and 34 patients that met the criteria for the modified intent-to-treat population are included in the efficacy analysis. The median progression-free survival was 9.1 months. There were 13 patients with objective responses for an objective response rate of 38% and 29% with a median duration response of 5.5 months. The clinical benefit rate at 16 weeks was 76%. A CA-125 response occurred in 19 of 26 patients . Rebastinib in combination with paclitaxel was generally well tolerated at 50 mg BID, and most common treatment-emergent adverse events were Grade 1 or 2. Four patients experienced serious adverse events at least possibly related to rebastinib including reversible muscular weakness, constipation, fatigue, and urinary tract infection . Based on the strength of these findings, the Company has begun planning for a pivotal study in PROC that is anticipated to start in 2022, subject to feedback from regulators. The Phase 1/2 study of vimseltinib is an open-label, multicenter study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of vimseltinib in patients with solid tumors and TGCT. The data is from patients with TGCT in both the Phase 1 dose escalation portion of the study and from cohort A in the Phase 2 expansion portion of the study. Cohort A includes TGCT patients with no prior anti-CSF1/CSF1R and cohort B includes patients with prior anti-CSF1/CSF1R. As of the June 7, 2021 cutoff date, 68 TGCT patients were treated with vimseltinib and included in the safety population, including 32 TGCT patients enrolled in the Phase 1 dose escalation portion of the study and 36 TGCT patients enrolled in cohort A in the Phase 2 portion of the study. Efficacy data presented is from 51 TGCT patients, including all 32 TGCT patients enrolled in the Phase 1 dose escalation portion of the study and 19 TGCT patients enrolled in cohort A in the Phase 2 portion of the study that were evaluable for efficacy as of the cutoff date. Dose Cohorts and Demographics: 32 patients enrolled in Phase 1 and 36 patients enrolled in Phase 2 cohort A: Phase 1 cohort 5: 30 mg loading dose daily for five days followed by a maintenance dose of 30 mg twice a week. Phase 1 cohort 8: 30 mg loading dose daily for three days followed by a maintenance dose of 10 mg daily. Phase 1 cohort 9: 20 mg loading dose daily for three days followed by a maintenance dose of 6 mg daily. Phase 2 cohort A: 30 mg twice weekly . 12 out of 32 patients in Phase 1 and 32 out of 36 patients in Phase 2 cohort A had at least one prior surgery; five patients in Phase 1 and two patients in Phase 2 cohort A had received at least one prior systematic therapy. 51 patients were evaluable for efficacy by Response Evaluation Criteria In Solid Tumors v1.1 at the data cutoff in Phase 1 across all dose cohorts and in Phase 2 cohort A; response data is based on independent central radiologic review with the exception of one patient who had a local assessment, and for whom no central assessment was performed. Updated Preliminary Efficacy and Duration of Treatment: Of the 51 efficacy-evaluable patients in Phase 1 across all dose cohorts and in the Phase 2 cohort A, 24 patients had a response resulting in an ORR of 47%. Of the 32 patients in Phase 1, 16 patients achieved an objective response for an ORR of 50% with durable responses observed across all dose cohorts, including one complete response in cohort 5. The median duration of treatment for all patients was 10.1 months. 72% of patients remain active in the study as of the data cutoff date. Of the 36 patients enrolled in Phase 2 cohort A, 19 patients were evaluable for efficacy, of which there were eight patients with an objective response for an ORR of 42%. Of the 19 patients, 10 had more than one follow-up imaging assessment and two responses occurred at later scans. The median duration of treatment for all patients was 1.9 months. The study is ongoing and follow-up evaluation is continuing with 83% of patients remaining active as of the data cutoff date. Safety and Tolerability: In both Phase 1 and Phase 2 cohort A, treatment with vimseltinib was generally well tolerated in patients with TGCT. Two patients discontinued treatment due to a TEAE in Phase 1 and one patient discontinued treatment due to an TEAE in Phase 2 cohort A. Two patients experienced SAEs at least possibly related to vimseltinib, including metabolic encephalopathy and vaginal hemorrhage in Phase 1; no treatment-related SAEs were reported in Phase 2 cohort A. The majority of the common TEAEs were Grade 2 or lower. Observed transaminase, pancreatic, and creatine phosphokinase enzyme elevations were mostly low grade, asymptomatic, and consistent with mechanism of action of CSF1R inhibitors. No abnormalities in bilirubin levels were reported.

Neutral

Deciphera Pharmaceuticals, Inc. - Special Call

2021-09-10 11:00:00

To review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021

Neutral

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022

2021-09-04 12:00:00

Cambridge Innovation Institute, LLC, SCOPE Summit 2022, Feb 07, 2022 through Feb 10, 2022. Venue: Orlanda, Florida, United States.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 02:45 PM

2021-09-02 11:00:00

Deciphera Pharmaceuticals, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-09-2021 02:45 PM. Venue: New Windsor, United States. Speakers: Steven L. Hoerter, President, CEO & Director.

Neutral

Deciphera Pharmaceuticals, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021

2021-08-23 12:06:00

Deciphera Pharmaceuticals, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris, France.

Neutral

Deciphera Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 03, 2021

2021-07-27 11:00:00

Deciphera Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Aug 03, 2021

Neutral

Deciphera Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

2021-07-27 11:00:00

Deciphera Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Positive

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

2021-06-30 20:01:00

Deciphera Pharmaceuticals, Inc. announced dose administration for the first patient in the Phase 1, multicenter, open-label, first-in-human study of DCC-3116. DCC-3116 is an investigational ULK kinase inhibitor designed to inhibit autophagy and is being studied as a single agent and in combination with trametinib, a U.S. Food and Drug Administration (FDA) approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. Autophagy, a catabolic process in which cells recycle components to generate energy, is often upregulated in cancer cells when cells are stressed or damaged due to anti-cancer treatments. The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations. In preclinical studies, DCC-3116 was observed to potently and durably inhibit autophagy in RAS and RAF mutant cancer cell lines through the inhibition of ULK kinase. In addition, in preclinical studies, DCC-3116 also blocked the increase in autophagy induced by inhibitors of the MAPK pathway as a resistance mechanism. The Company’s in vitro and in vivo studies have demonstrated that DCC-3116 in combination with inhibitors of the MAPK pathway may block the growth of cancers caused by RAS or RAF mutations. The clinical development plan for DCC-3116 will focus on documented RAS and RAF cancer mutations, which utilize autophagy for tumor growth and survival. The Phase 1, multicenter, open-label, first-in-human study will evaluate DCC-3116 as a single agent and in combination with trametinib, an FDA-approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. Assuming positive results in the dose escalation phase, combination expansion cohorts are currently planned in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS or BRAF mutations, non-small cell lung cancer (NSCLC) with KRAS, NRAS, or BRAF mutations, colorectal cancer (CRC) with KRAS, NRAS, or BRAF mutations, and melanoma with NRAS or BRAF mutations. Combination expansion cohorts are planned to evaluate DCC-3116 in combination with trametinib.

Fundamental Summary

According to their recent financial report, which was published on 2022-05-04, Deciphera Pharmaceuticals had several impressive financial metrics that should make them more attractive than their peers going forward. Their positive growth and income factors indicate that Deciphera Pharmaceuticals is likely to continue to produce impressive results for the foreseeable future, as well. There should be significant upside potential for the stock looking forward. We therefore gave Deciphera Pharmaceuticals a total score of 75 out of 100 and a HOLD recommendation.

Deciphera Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 29.22 million compared to USD 25.16 million a year ago. Net loss was USD 46.89 million compared to USD 61.3 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 1.06 a year ago.

Business Description

Deciphera Pharmaceuticals, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals was founded in 2003 and is headquartered in Waltham, Massachusetts.

Sector Overview

Deciphera Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Deciphera Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 385.5 -10.2% 71
Liabilities 113.9 -8.7% 56
Price to Book 2.0 10.0% 63
Cash & Equivalents 95.3 9.5% 82
Equity 271.6 -10.9% 38
EBITDA -249.0 5.7% 79
Total Revenues 100.2 4.2% 60
Parameter Value Change Score
Return on Equity -73.7 -4.3% 70
Net Cashflow -106.3 -117.7% 87
Capital Expenditure -1.3 32.3% 95
Asset Turnover 0.2 13.9% 91
Free Cashflow -3.9 7.2% 79

* All values are TTM

The below chart reflects Deciphera Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Deciphera Pharmaceuticals's peer average final assessment score stands on 62.0, Deciphera Pharmaceuticals's score is 75.

  •  DCPH
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Deciphera Pharmaceuticals's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Deciphera Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 13.35
52W Low 6.87
52W High 37.15
5D MA 13.58
50D MA 11.11
200D MA 14.23
MACD 0.71
RSI 18.34
STOCH 82.25

Balance Sheet Analysis

Deciphera Pharmaceuticals appears likely to maintain its strong balance sheet metrics and momentum going forward. Deciphera Pharmaceuticals's management was effective in improving its cash and cash equivalents metrics, which now sit at 95.3. This represents 9.5% change from the last reporting period. This performance is significantly more impressive than its peers and competitors. It suggests that their stock price has room to grow to reflect its actual intrinsic value. The company's cash and cash equivalents movement, therefore, received a grade of 82. Also, Deciphera Pharmaceuticals assets on their balance sheet, moved to 385.5, which is a -10.2% change from the last period. This performance is interesting in comparison to its peers and competitors. Consequently, their asset movement received a grade of 71. That said, one metric, Equity, stood out as particularly concerning. Deciphera Pharmaceuticals management produced disappointing equity metrics this period, which stood at 271.6, representing a -10.9% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Consequently, their equity movement received a grade of 38. Consequently, the company's balance sheet earned a rank of 61.

Parameter Value Change Score
Assets 385.5 -10.2% 71
Liabilities 113.9 -8.7% 56
Price to Book 2.0 10.0% 63
Cash & Equivalents 95.3 9.5% 82
Equity 271.6 -10.9% 38
* All values are TTM

The below chart describes Deciphera Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Deciphera Pharmaceuticals received a balance sheet score of 61, the average of its peers stands on 64.0.

  •  DCPH
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Deciphera Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Deciphera Pharmaceuticals's management was effective in improving its EBIDTA, which now sits at -249.0 and represents a 5.7% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Therefore, its EBITDA component earned a score of 79. Also, Deciphera Pharmaceuticals's reported return on equity (ROE) ratio was -73.7, representing a change of -4.3%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 70. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Deciphera Pharmaceuticals management did an underwhelming job managing revenue efficiency this past period. Deciphera Pharmaceuticals's revenue efficiency is 100.2 according to the metrics in the current filing, which represents a 4.2% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Its revenue efficiency, therefore, received a grade of 60. Therefore, we scored its income statement a 77.

Parameter Value Change Score
EBITDA -249.0 5.7% 79
Total Revenues 100.2 4.2% 60
Return on Equity -73.7 -4.3% 70
* All values are TTM

The below chart describes Deciphera Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Deciphera Pharmaceuticals received a income statement score of 77 , the average of its peers stands on 62.0.

  •  DCPH
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Capex and Asset Turnover, are driving the positive outlook for Deciphera Pharmaceuticals's financial strength. Deciphera Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -1.3, which represents a 32.3% change from the last period. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. The company's CapEx movement, therefore, received a grade of 95. Also, Deciphera Pharmaceuticals's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Deciphera Pharmaceuticals recorded asset turnover of 0.2, which represents a 13.9% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Correspondingly, their asset turnover movement received a grade of 91. However, one discouraging result, Free Cash flow, stood out. Free cash flow numbers published by Deciphera Pharmaceuticals were -3.9, which was a 7.2% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 79. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 94.

Parameter Value Change Score
Net Cashflow -106.3 -117.7% 87
Capital Expenditure -1.3 32.3% 95
Asset Turnover 0.2 13.9% 91
Free Cashflow -3.9 7.2% 79
* All values are TTM

The below chart describes Deciphera Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Deciphera Pharmaceuticals received a cash flow score of 94, the average of its peers stands on 65.0.

  •  DCPH
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.